natgillin/translations-raw huggingface dataset:
Prior to launch in each Member State, the MAH shall agree the final educational material with the competent authority in that Member State comprising of information provided to all healthcare professionals expected to prescribe the product on the correct and safe use of the pre-filled pen and a Patient Alert Card which is to be given to patients using Enbrel. 
Imetnik dovoljenja za promet z zdravilom se mora pred pričetkom trženja napolnjenega peresnika v vsaki državi članici s pristojnim organom v tej državi dogovoriti glede končnega izobraževalnega gradiva, sestavljenega iz informacij za vse zdravstvene delavce, za katere se pričakuje, da bodo predpisovali to zdravilo, glede pravilne in varne uporabe napolnjenega peresnika, ter opozorilne kartice za bolnika, ki jo morajo izročiti bolnikom, ki se zdravijo z zdravilom Enbrel.
The use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of psoriasis has not been studied. 
Uporaba zdravila Enbrel v kombinaciji z drugimi sistemskimi zdravljenji ali fototerapijo za zdravljenje psoriaze ni raziskana.
Two large clinical trials evaluating the use of Enbrel in the treatment of CHF were terminated early due to lack of efficacy. 
Dve veliki klinični preskušanji za ovrednotenje uporabe zdravila Enbrel pri zdravljenju KSP sta bili predčasno prekinjeni zaradi slabe učinkovitosti zdravila.
Treatment with Enbrel 25 mg resulted in substantial improvement at 12 months, with about 44% of patients achieving a normal HAQ score (less than 0.5). 
Z zdravljenjem s 25 mg zdravila Enbrel so dosegli bistveno izboljšanje pri 12 mesecih - približno 44 % bolnikov je doseglo normalen rezultat HAQ (manj kot 0,5).
Some children and teenage patients who have received Enbrel or other medicines that work the same way as Enbrel have developed cancers, including unusual types, which sometimes resulted in death. 
Pri nekaterih otrocih in mladostnikih, ki so prejemali zdravilo Enbrel ali druga podobna zdravila z enakim načinom delovanja kot zdravilo Enbrel, se je razvil rak, vključno z neobičajnimi oblikami, ki se je včasih končal s smrtjo.
The known side effects of Enbrel include the following in groups of decreasing frequency: 
Znani neželeni učinki zdravila Enbrel so v nadaljevanju navedeni v skupinah po padajoči pogostnosti:
What you need to know before you use Enbrel 
Kaj morate vedeti, preden boste uporabili zdravilo Enbrel
The effect of Enbrel on radiographic progression was maintained in patients who continued on treatment during the second year. 
Učinek zdravila Enbrel na radiografsko napredovanje bolezni se je ohranjal pri bolnikih, ki so nadaljevali zdravljenje še drugo leto.
Enbrel + Methotrexate 
Enbrel + metotreksat
Because immunoglobulins, in common with many medicinal products, can be excreted in human milk, a decision must be made whether to discontinue breast-feeding or to discontinue Enbrel therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. 
Ker se imunoglobulini, tako kot mnoga druga zdravila, lahko izločajo v mleko pri človeku, se je treba odločiti, ali bo med zdravljenjem z zdravilom Enbrel bolnica prenehala dojiti ali pa bo med dojenjem prekinila zdravljenje s tem zdravilom, pri čemer je treba upoštevati tako korist dojenja za otroka kot korist zdravljenja za mater.
What Enbrel is and what it is used for What you need to know before you use Enbrel How to use Enbrel 
Kaj je zdravilo Enbrel in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Enbrel Kako uporabljati zdravilo Enbrel
To help you remember, it may be helpful to write in a diary which day(s) of the week Enbrel should be used. 
Da si boste lažje zapomnili, vam bo morda pomagalo, če si v koledarju zabeležite dan (dneve) v tednu, ko morate uporabiti zdravilo Enbrel.
Your doctor will determine the correct dose for the child and will prescribe an appropriate strength of Enbrel (10 mg, 25 mg or 50 mg). 
Natančen odmerek za otroka bo določil zdravnik in predpisal ustrezno jakost zdravila Enbrel (10 mg, 25 mg ali 50 mg).
In addition, one study found more birth defects when the mother had received Enbrel in pregnancy, compared with mothers who had not received Enbrel or other similar medicines (TNF-antagonists), but there was no particular kind of birth defect reported. 
Poleg tega so v eni študiji ugotovili več prirojenih napak, kadar je mati med nosečnostjo prejemala zdravilo Enbrel, v primerjavi z materami, ki niso prejemale zdravila Enbrel ali drugih podobnih zdravil (antagonistov TNF), vendar niso poročali o nobeni določeni vrsti prirojene okvare.
In this situation, the benefit/risk balance of Enbrel therapy should be very carefully considered. 
V takem primeru je treba zelo skrbno pretehtati razmerje med koristmi in tveganji zdravljenja z zdravilom Enbrel.
Enbrel works by reducing the inflammation associated with certain diseases. 
Deluje tako, da zmanjšuje vnetje, ki spremlja določene bolezni.
It is recommended that you record the date that Enbrel is removed from the refrigerator and the date after which Enbrel should be discarded (no more than 4 weeks following the removal from the refrigerator). 
Priporočljivo si je zabeležiti datum odvzema zdravila Enbrel iz hladilnika in datum, po katerem je treba zdravilo Enbrel zavreči (do 4 tedne po odvzemu iz hladilnika).
If the window is not completely purple, contact your nurse or pharmacist for assistance, since the pen may not have injected the Enbrel solution completely. 
Če okence ni povsem vijolično, za pomoč prosite medicinsko sestro ali farmacevta, saj peresnik raztopine zdravila Enbrel morda ni injiciral v celoti.
What Enbrel is and what it is used for 
Kaj je zdravilo Enbrel in za kaj ga uporabljamo
For patients with multiple symmetrical painful or swollen joints (e.g., hands, wrists and feet), Enbrel can slow down the structural damage to those joints caused by the disease. 
Pri bolnikih z več simetrično prizadetimi bolečimi ali oteklimi sklepi (npr. dlanmi, zapestji ali stopali) lahko zdravilo Enbrel upočasni razvoj strukturnih okvar teh sklepov, ki jih povzroča bolezen.
If you received Enbrel during pregnancy, your baby may have a higher risk of getting an infection. 
Če ste med nosečnostjo prejeli zdravilo Enbrel, lahko pri vašem dojenčku obstaja povečano tveganje za razvoj okužbe.
Serious infections occurred in 6.3% of rheumatoid arthritis patients treated with Enbrel for up to 48 months. 
Resne okužbe so se pojavile pri 6,3 % bolnikov z revmatoidnim artritisom, ki so prejemali zdravilo Enbrel do 48 mesecev.
Do not use the solution if it is discoloured, cloudy, or if particles other than those described above are present. 
Raztopine ne uporabljajte, če je drugačne barve, motna ali če so prisotni delci, ki ne ustrezajo opisu zgoraj.
If you have used more Enbrel than you should (either by injecting too much on a single occasion or by using it too frequently), talk to a doctor or pharmacist immediately. 
Če ste uporabili večji odmerek zdravila Enbrel, kot bi smeli (bodisi ste ga naenkrat injicirali preveč bodisi prepogosto), se nemudoma posvetujte z zdravnikom ali farmacevtom.
After discontinuation of Enbrel, symptoms of arthritis generally returned within a month. 
Po prekinitvi zdravljenja z zdravilom Enbrel so se simptomi artritisa največkrat ponovno pojavili že v enem mesecu.
The impact of long-term treatment with Enbrel on the development of autoimmune diseases is unknown. 
Vpliv dolgotrajnega zdravljenja z zdravilom Enbrel na razvoj avtoimunskih bolezni ni znan.
On the basis of the scientific conclusions for etanercept (except for biosimilars) the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing etanercept (except for biosimilars) is unchanged subject to the proposed changes to the product information 
Na podlagi znanstvenih zaključkov za etanercept (razen podobnih bioloških zdravil) odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil(-a), ki vsebuje(-jo) etanercept (razen podobnih bioloških zdravil), nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
Enbrel treatment may increase mortality in patients with established sepsis. 
Zdravljenje z zdravilom Enbrel lahko zveča smrtnost pri bolnikih z dokazano sepso.
The safety and efficacy profiles of the two Enbrel treatment regimens were comparable at week 8 in their effect on signs and symptoms of RA; data at week 16 did not show comparability (non-inferiority) between the two regimens. 
Profil varnosti in učinkovitosti obeh shem zdravljenja z zdravilom Enbrel je bil po 8 tednih primerljiv glede učinka na znake in simptome revmatoidnega artritisa; podatki po 16 tednih niso pokazali primerljivosti (neinferiornosti) med obema shemama.
If you feel that the effect of Enbrel is too strong or too weak, talk to your doctor or pharmacist. 
Če menite, da je učinek zdravila Enbrel premočan ali prešibak, se posvetujte z zdravnikom ali farmacevtom.
If you use more Enbrel than you should 
Če ste uporabili večji odmerek zdravila Enbrel, kot bi smeli
Do NOT use Enbrel if all the powder in the vial is not dissolved within 10 minutes. 
NE uporabite zdravila Enbrel, če se ves prašek v viali ni raztopil v 10 minutah.
If inactive (‘latent') tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis therapy before the initiation of Enbrel, and in accordance with local recommendations. 
Če se ugotovi neaktivna ('latentna') tuberkuloza, je treba pred uvedbo zdravila Enbrel in v skladu z nacionalnimi priporočili začeti zdravljenje latentne tuberkuloze s tuberkulostatiki.
Enbrel did not induce lethality or notable signs of toxicity in mice or rats following a single subcutaneous dose of 2000 mg/kg or a single intravenous dose of 1000 mg/kg. 
Zdravilo Enbrel ni povzročilo smrtnosti ali pomembne toksičnosti pri miših ali podganah po enkratnem subkutanem odmerku 2.000 mg/kg ali enkratnem intravenskem odmerku 1.000 mg/kg.
Patients who develop a new infection while undergoing treatment with Enbrel should be monitored closely. 
Bolnike, pri katerih se med zdravljenjem z zdravilom Enbrel pojavi nova okužba, je treba skrbno spremljati.
Although not conclusive, data from one of these trials suggest a possible tendency toward worsening CHF in those patients assigned to Enbrel treatment. 
Izsledki sicer še niso dokončni, vendar podatki iz enega od teh preskušanj kažejo na morebitno tendenco k poslabšanju KSP pri bolnikih, zdravljenih s tem zdravilom.
There have been reports of worsening of hepatitis C in patients receiving Enbrel. 
Poročali so o poslabšanju hepatitisa C pri bolnikih, ki so prejemali zdravilo Enbrel.
• Alcohol abuse: Enbrel should not be used for the treatment of hepatitis related to alcohol abuse. 
Zloraba alkohola: Zdravila Enbrel ne smete uporabljati za zdravljenje hepatitisa, povezanega z zlorabo alkohola.
Within the organ system classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare 
Znotraj organskih sistemov so neželeni učinki navedeni po pogostnosti (število bolnikov, pri katerih se pričakuje pojav učinka), z uporabo naslednjih kategorij: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Enbrel is also prescribed for the treatment of the following diseases in children and adolescents 
Zdravilo Enbrel se predpisuje tudi za zdravljenje naslednjih bolezni pri otrocih in mladostnikih:
Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking into consideration that the mean elimination half-life of etanercept is approximately 70 hours (range 7 to 300 hours). 
Pred zdravljenjem z zdravilom Enbrel, med njim in po njem je treba bolnike pregledati glede okužb in pri tem upoštevati, da je povprečni razpolovni čas izločanja etanercepta iz telesa približno 70 ur (razpon 7 do 300 ur).
Children and adults taking Enbrel may have an increased risk of developing lymphoma or another cancer. 
Pri otrocih in odraslih, ki prejemajo zdravilo Enbrel, je morda tveganje za nastanek limfoma ali druge oblike raka večje.
Other medicines and Enbrel 
Druga zdravila in zdravilo Enbrel
PsARC Month 3 
PsARC 3. mesec b
• Push the plunger in VERY SLOWLY until all the water for injections is in the vial. 
ZELO POČASI potiskajte bat v brizgo, dokler ne iztisnete vse vode za injekcije v vialo.
Compared to placebo, treatment with Enbrel resulted in statistically significant improvement in the ASAS 40, ASAS 20 and ASAS 5/6. 
Zdravljenje z zdravilom Enbrel je v primerjavi s placebom povzročilo statistično pomembno izboljšanje ASAS 40, ASAS 20 in ASAS 5/6.
The 10 mg Enbrel dose had consistently less effect on structural damage than the 25 mg dose. 
10 mg odmerek zdravila Enbrel je imel ves čas manjši učinek na strukturno poškodbo sklepov kot 25 mg odmerek.
If active tuberculosis is diagnosed, Enbrel therapy must not be initiated. 
Če je postavljena diagnoza aktivne tuberkuloze, se zdravljenja z zdravilom Enbrel ne sme uvesti.
Enbrel was significantly better than placebo in all measures of disease activity (p < 0.001), and responses were similar with and without concomitant methotrexate therapy. 
Zdravilo Enbrel je bilo pomembno boljše kot placebo po vseh kriterijih aktivnosti bolezni (p < 0,001) in odzivi so bili podobni, ne glede na sočasno zdravljenje z metotreksatom.
In patients who develop HBV infection, Enbrel should be stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated. 
Pri bolnikih, pri katerih se razvije okužba s HBV, je treba zdravljenje z zdravilom Enbrel prekiniti in uvesti učinkovito protivirusno ter ustrezno podporno zdravljenje.
After preparing the Enbrel solution, immediate use is recommended (up to a maximum of 6 hours). 
Po pripravi naj se raztopina zdravila Enbrel po možnosti uporabi takoj (v največ 6 urah).
Adding water for injections e. 
Dodajanje vode za injekcije e.
A total of 401 patients were enrolled, from which 203 were treated with Enbrel. 
Sodeloval je 401 bolnik in od tega so bili 203 zdravljeni z zdravilom Enbrel.
Such symptoms may point to the existence of potentially life-threatening blood disorders, which may require discontinuation of Enbrel. 
Ti simptomi namreč lahko kažejo na pojav življenjsko ogrožajoče bolezni krvi, pri kateri bo zdravljenje z zdravilom Enbrel morda treba prekiniti.
For psoriatic arthritis patients with multiple joint involvement, Enbrel can improve your ability to do normal daily activities. 
Pri bolnikih s psoriatičnim artritisom in prizadetostjo več sklepov lahko zdravilo Enbrel izboljša sposobnost opravljanja običajnih vsakdanjih dejavnosti.
The disability index score was significantly improved at all timepoints in psoriatic arthritis patients treated with Enbrel, relative to placebo (p < 0.001). 
Rezultat indeksa invalidnosti je bil bistveno boljši v vseh časovnih točkah pri bolnikih s psoriatičnim artritisom, zdravljenih z zdravilom Enbrel, v primerjavi s placebom (p < 0,001).
• The risk of Congestive Heart Failure (CHF). 
• tveganje za kongestivno srčno popuščanje (KSP)
A placebo-controlled trial, in which 89 adult patients were treated with Enbrel in addition to standard therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of 25 months, has not shown Enbrel to be an effective treatment for Wegener's granulomatosis. 
S placebom nadzorovano preskušanje, v katerem je 89 odraslih bolnikov poleg standardnega zdravljenja (vključno s ciklofosfamidom ali metotreksatom in glukokortikoidi) jemalo zdravilo Enbrel z medianim časom zdravljenja 25 mesecev, ni pokazalo učinkovitosti zdravila Enbrel za zdravljenje Wegenerjeve granulomatoze.
The difference between Enbrel alone and methotrexate alone was also significant (p<0.05). 
Pomembna je bila tudi razlika med monoterapijo z zdravilom Enbrel in monoterapijo z metotreksatom (p < 0,05).
Autoantibody formation Treatment with Enbrel may result in the formation of autoimmune antibodies (see section 4.8). 
Tvorba avtoprotiteles Zdravljenje z zdravilom Enbrel lahko sproži nastajanje avtoimunskih protiteles (glejte poglavje 4.8).
If the needle is not correctly lined up, you will feel constant resistance as it goes through the stopper and no “pop”. 
Če igla ne bo pravilno poravnana, boste pri prodiranju skozi zamašek ves čas čutili odpor in ne bo “poka”.
Consequently, Enbrel should not be used in patients for the treatment of alcoholic hepatitis. 
Zato zdravila Enbrel ne smemo uporabljati pri bolnikih za zdravljenje alkoholnega hepatitisa.
Method of administration Enbrel is administered by subcutaneous injection (see section 6.6). 
Način uporabe Zdravilo Enbrel se daje s subkutano injekcijo (glejte poglavje 6.6).
The incidence of non-cutaneous malignancies of various types was significantly higher in patients treated with Enbrel than in the control group. 
Pojavnost nekožnih malignih obolenj različnih tipov je bila pomembno večja pri bolnikih, zdravljenih z zdravilom Enbrel, kot pri tistih v kontrolni skupini.
If any serious allergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and appropriate therapy initiated. 
Če se pojavi kakršnakoli resna alergijska ali anafilaktična reakcija, je treba zdravljenje s tem zdravilom takoj prekiniti in uvesti ustrezno zdravljenje.
It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating Enbrel therapy (see Vaccinations, above). 
Za pediatrične bolnike priporočamo, da pred začetkom zdravljenja z zdravilom Enbrel, če je le mogoče, opravijo vsa cepljenja v skladu z veljavnimi smernicami za cepljenje (glejte Cepljenja zgoraj).
These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 event per patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events per patient year). 
Pojavljali so se glavoboli (19 %, 1,7 dogodka na bolnik-leto), navzea (9 %, 1,0 dogodek na bolnik-leto), bolečine v trebuhu (19 %, 0,74 dogodka na bolnik-leto) in bruhanje (13 %, 0,74 dogodka na bolnik-leto).
Based on the review of the literature and spontaneous reporting presented in this PSUSA, covering the period from 03 February 2018 to 02 February 2019, as well as cumulative data since the European birth date, the PRAC considered that a causal relationship between inflammatory bowel disease and etanercept cannot be excluded and therefore recommends that the product information of medicinal products containing the active substance etanercept should be updated as follows: update of section 4.8 of the SmPC to add inflammatory bowel disease with a frequency uncommon. 
Na podlagi pregleda literature in spontanega poročanja, predstavljenega v tej enotni oceni redno posodobljenih poročil o varnosti zdravila (PSUSA), ki zajema obdobje od 3. februarja 2018 do 2. februarja 2019, ter kumulativnih podatkov od datuma pridobitve dovoljenja za promet z zdravilom v Evropi, odbor PRAC meni, da ni mogoče izključiti vzročne povezanosti med vnetno črevesno boleznijo in etanerceptom, zato priporoča posodobitev informacij o zdravilih, ki vsebujejo učinkovino etanercept, in sicer kot sledi: posodobitev poglavja 4.8 povzetka glavnih značilnosti zdravila tako, da bo vključevalo vnetno črevesno bolezen s pogostnostjo ''občasni''.
Enbrel is not recommended for the treatment of Wegener's granulomatosis. 
Zdravila Enbrel ni priporočljivo uporabljati za zdravljenje Wegenerjeve granulomatoze.
During the first 12 weeks of the double-blind treatment period, patients received placebo or one of the above three Enbrel doses. 
V prvih 12 tednih dvojno slepega obdobja zdravljenja so bolniki dobivali placebo ali enega od navedenih odmerkov zdravila Enbrel.
Patients who “failed to respond to” in the target population is defined by insufficient response (PASI<50 or PGA less than good), or worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long duration to assess response with at least each of the three major systemic therapies as available. 
Bolnike v ciljni populaciji, ki ''se niso odzvali'', opredeljuje nezadosten odziv (PASI  50 ali PGA [PGA - Physician Global Assessment] manj kot dober) ali poslabšanje bolezni med zdravljenjem, ko je bolnik prejemal najmanj vsako od treh glavnih razpoložljivih sistemskih zdravljenj v zadostnem odmerku in dovolj časa, da je bilo mogoče oceniti odziv.
The efficacy of Enbrel versus other systemic therapies in patients with moderate to severe psoriasis (responsive to other systemic therapies) has not been evaluated in studies directly comparing Enbrel with other systemic therapies. 
Učinkovitosti zdravila Enbrel v primerjavi z drugimi sistemskimi zdravljenji pri bolnikih z zmerno do hudo psoriazo (ki se odziva na druga sistemska zdravljenja) niso ovrednotili s študijami, v katerih bi neposredno primerjali zdravilo Enbrel z drugimi sistemskimi terapijami.
Treatment with Enbrel should not be initiated in patients with active infections, including chronic or localised infections. 
Zdravljenja z zdravilom Enbrel ne smete uvesti pri bolnikih z aktivnimi okužbami, vključno s kroničnimi ali lokaliziranimi okužbami.
Enbrel is prescribed for the treatment of the following diseases in children and adolescents 
Zdravilo Enbrel se predpisuje za zdravljenje naslednjih bolezni pri otrocih in mladostnikih:
There was some evidence to support a benefit of re-treatment with Enbrel in patients initially responding to treatment. 
Nekaj podatkov kaže na ugoden odziv na ponovno zdravljenje z zdravilom Enbrel pri bolnikih, ki so se prvotno odzvali na zdravljenje.
Start again with a new Enbrel vial, water for injections, syringe, needle and swabs. 
V tem primeru začnite z novo vialo zdravila Enbrel, vodo za injekcije, brizgo, iglo in blazinicami.
Your doctor or nurse will tell you how to inject Enbrel. 
Zdravnik ali medicinska sestra vas bosta natančno poučila, kako si injicirate zdravilo Enbrel.
• Tuberculosis: As cases of tuberculosis have been reported in patients treated with Enbrel, your doctor will check for signs and symptoms of tuberculosis before starting Enbrel. 
Tuberkuloza: Ker so pri bolnikih, ki so se zdravili z zdravilom Enbrel, poročali o primerih tuberkuloze, se bo vaš zdravnik prepričal, da nimate znakov ali simptomov tuberkuloze, preden se boste začeli zdraviti z zdravilom Enbrel.
Another study found no increased risk of birth defects when the mother had received Enbrel in pregnancy. 
V drugi študiji niso ugotovili povečanega tveganja za prirojene napake, kadar je mati med nosečnostjo prejemala zdravilo Enbrel.
However, it cannot be excluded that the combination of Enbrel with methotrexate could be associated with an increase in the rate of infections. 
Vendar pa ni mogoče izključiti možnosti, da se lahko stopnja pogostnosti okužb pri zdravljenju s kombinacijo zdravila Enbrel in metotreksata poveča.
Paediatric population See Summary of the safety profile, above. 
Glejte Povzetek varnostnega profila zgoraj.
If you stop using Enbrel 
Če ste prenehali uporabljati zdravilo Enbrel
If re-treatment with Enbrel is indicated, the same guidance on treatment duration should be followed. 
Če je indicirano ponovno zdravljenje z zdravilom Enbrel, se moramo ravnati po istih smernicah glede trajanja zdravljenja.
Although no clinical trials have been performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other TNF antagonists in patients with multiple sclerosis have shown increases in disease activity. 
Čeprav niso opravili kliničnih preskušanj za ovrednotenje zdravljenja z zdravilom Enbrel pri bolnikih z multiplo sklerozo, so klinična preskušanja drugih antagonistov TNF pri teh bolnikih pokazala zvečano aktivnost bolezni.
Enbrel has not been studied in children aged less than 2 years. 
Zdravila Enbrel niso preskušali pri otrocih, mlajših od 2 let.